MorphoSys AG has announced that the company has earned a milestone payment with Bayer's initiation of a global phase 2 clinical study designed to support registration of anetumab ravtansine (BAY 94-9343).
Anetumab ravtansine, an antibody-drug conjugate (ADC) targeting mesothelin, is a potential new treatment for mesothelioma developed by Bayer using MorphoSys's HuCAL technology. Further financial details were not disclosed.
"We are delighted to see our partner Bayer moving anetumab ravtansine into a clinical study designed to support its registration in mesothelioma, an indication with high medical need", commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "This is the fourth antibody derived from the MorphoSys technology platform to advance into decisive stages of clinical development. This again reflects the increasing maturity and value of the MorphoSys pipeline comprising both proprietary and partnered programs."
MorphoSys's collaboration with Bayer has resulted in two clinical programs to date. In total, MorphoSys's partnered and proprietary clinical pipeline currently comprises 25 unique antibody molecules which are currently being evaluated in more than 50 clinical trials.